Non-ischemic Cardiomyopathy denials in California external review
In the California DMHC record, independent physician reviewers decided 20 published external-review cases involving non-ischemic cardiomyopathyand overturned the plan’s denial in 65%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
Most-fought treatments for non-ischemic cardiomyopathy
| Category | Decisions | Overturned |
|---|---|---|
| Wearable Cardioverter Defibrillator | 7 | 71.4% |
| Zoll Life Vest | 5 | 40% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 13 | 69.2% |
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 7 | 57.1% |
What the reviewers wrote
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for mobile cardiac outpatient telemetry. Mobile cardiac outpatient telemetry (MCOT) has emerged as a standard tool in the evaluation of patients with suspected cardiac arrhythmia. While traditional Holter monitors provide continuous electrocardiogram (ECG) monitoring, this modality is generally only available for 24 to 48 hours. Current MCOT systems with advanced technology permit nearly continuous, automatic, and, with some systems, real-time monitoring. These systems are often smaller and less intrusive to patients, leveraging patch-style devices rather than cumbersome, multi-lead systems.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested reimbursement and prospective authorization and coverage for Zoll LifeVest. Primary prevention implantable cardioverter-defibrillator (ICD) is recommended to prevent sudden cardiac arrest (SCA) and death due to ventricular tachycardia/fibrillation (VT/VF) in patients with heart failure and left ventricular ejection fraction (LVEF) of less than 36% only after a minimum of three months of guideline-directed medical therapy (GDMT). Several studies have examined whether wearable cardioverter-defibrillator (WCD) offers protection against SCA/death during these three months where GDMT is prescribed and titrated.
Where the denial was upheld
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for a Zoll LifeVest for treatment of the enrollee who had a recent episode of tachycardia. Findings: 2/3 of the physician reviewers found that based on the records provided, the patient has been diagnosed with a newly recognized nonischemic cardiomyopathy, a left ventricular ejection fraction of about 30 to 35% and sustained wide complex tachycardia of uncertain origin in the absence of documented syncope. In this circumstance, since the origin of the tachycardia is not clearly ventricular and may be supraventricular, further evaluation with an electrophysiology study is most appropriate to define the tachycardia prior to committing to a defibrillator (wearable of implantable).
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Zoll Life Vest for three (3) months. Findings: Three physician reviewers found that the superior efficacy of the device at issue has not been demonstrated in this clinical setting. Based on the records provided, this patient has been diagnosed with a newly recognized nonischemic cardiomyopathy. In this circumstance, there is potential for recovery of left ventricular function over time with medical therapy. Based on the records, there was no indication for an immediate placement of a defibrillator. The documentation did not indicate sustained or inducible ventricular tachycardia, syncope or aborted sudden cardiac arrest.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving non-ischemic cardiomyopathy, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY